Accessibility Menu
hVIVO Plc logo

hVIVO Plc(OTC) OPORF

Market Cap$75.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+5,582%
5 Year-74%
1 Year-54%
1 Month+27%
$0.11
+0.00%
+0.00Today
hVIVO Plc last closing stock price
MetricPriceDate
Last closeUSD 0.112026-06-12
hVIVO Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+27.29%USD 0.092026-01-02
1 month+27.29%USD 0.092026-01-02
3 month+27.29%USD 0.092026-01-02
Year to date-53.82%USD 0.242025-02-14
1 year-53.82%USD 0.242025-02-14
3 year-25.64%USD 0.152023-06-07
5 year-74.28%USD 0.432021-05-14
Since inception+5,581.7%USD 0.002020-06-05

hVIVO Plc Financials at a Glance

Market Cap

$75.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£110.75M

Net Income (TTM)

£4.66M

EPS (TTM)

-$0.01

P/E Ratio

-9.37

Dividend

$0.00

Beta (Volatility)

-0.17 (Low)

Price

$0.11

Volume

30,504

Open

$0.11

Previous Close

$0.11

Daily Range

$0.11 - $0.11

52-Week Range

$0.09 - $0.24

Estimated Earnings Date

Sep 15, 2026

OPORF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About hVIVO Plc

hVIVO plc operates as a contract research organization and pharmaceutical service provider, focusing on evaluating vaccines and antiviral medications through specialized human challenge clinical trials. The company serves a diverse clientele, including major pharmaceutical firms, governmental bodies, and public health agencies.

Products and Services
  • Human challenge clinical trials for various infectious diseases
  • Development of the 'Disease in Motion' platform for infectious disease data
  • Consultancy services in drug development and biometry
Growth Outlook
  • Expansion of human challenge study models, including COVID-19
  • Increased demand for vaccine evaluation services post-pandemic
  • Potential partnerships with technology firms for the 'Disease in Motion' platform
Financial Highlights
  • Recent quarterly revenue of $22.6 million, showing strong market presence
  • Trailing twelve months (TTM) revenue of $92.5 million, indicating growth
  • Net income of $12.2 million in the latest quarter, reflecting operational efficiency
hVIVO plc is positioned in the biotechnology sector, specializing in human challenge studies that provide critical data for vaccine and antiviral development. The company's innovative approach, particularly with the 'Disease in Motion' platform, aims to integrate diverse datasets for better understanding of infectious diseases. This platform is expected to attract interest from various sectors, including technology and pharmaceuticals, enhancing its market potential. The financial performance of hVIVO has shown promising trends, with a significant revenue increase in recent quarters. The latest quarterly results indicate a robust revenue stream, which is essential for sustaining growth and expanding operations. The company's focus on developing new study models and enhancing its service offerings positions it well for future growth, especially in a post-pandemic landscape where the demand for vaccine research remains high. Investors may find hVIVO's strategic initiatives and financial performance noteworthy as the company continues to navigate the evolving biotechnology landscape.
AI Generated • Jul 10, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Yamin Mohammed Khan

Website

www.hvivo.com

Headquarters

London, GL E1 1EQ, GB

OPORF Financials

Key Financial Metrics (TTM)

Gross Margin

-6.07%

Operating Margin

-13.13%

Net Income Margin

-12.48%

Return on Equity

-14.65%

Return on Capital

-0.66%

Return on Assets

-8.35%

Earnings Yield

-10.67%

Dividend Yield

0.00%

Payout Ratio

-22.89%

Stock Overview

Market Cap

$75.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

688.40M

Volume

30.50K

Avg. Volume

484.191

Financials (TTM)

Gross Profit

£59.81M

Operating Income

£6.55M

EBITDA

£17.59M

Operating Cash Flow

-£3.76M

Capital Expenditure

-£3.86M

Free Cash Flow

-£7.62M

Cash & ST Invst.

£14.30M

Total Debt

£14.79M

hVIVO Plc Performance Analysis

hVIVO Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 59,713,00817.8%
20232023-12-31GBP 69,664,35416.7%
20242024-12-31GBP 80,150,77715.1%
20252025-12-31GBP 61,641,681-23.1%
hVIVO Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3023.9%
Q42024-12-31-31.4%
Q22025-06-30-0.3%
Q42025-12-31-11.3%
hVIVO Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.00600.0%
20232023-12-31GBP 0.03N/A
20242024-12-31GBP 0.02-32.2%
20252025-12-31GBP -0.01N/A
hVIVO Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-56.8%
Q42024-12-313.9%
Q22025-06-30-102.5%
Q42025-12-31-4200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£22.58M

-24.8%

Gross Profit

-£5.93M

-175.8%

Gross Margin

-26.28%

N/A

Market Cap

$75.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$200.66K

N/A

Employees

376

N/A

Net Income

-£5.88M

-148.3%

EBITDA

-£3.23M

-147.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£14.30M

-61.3%

Total Debt

£14.79M

+18.0%

Accounts Receivable

£12.50M

+37.1%

Inventory

£691.00K

+62.2%

Long Term Debt

£12.30M

+1.1%

Short Term Debt

£2.49M

+578.2%

Return on Assets

-8.35%

N/A

Return on Invested Capital

-11.66%

N/A

Free Cash Flow

-£7.39M

-227.8%

Operating Cash Flow

-£6.57M

-162.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EVGRFChina Evergrande New Energy Vehicle Group Limited
$0.00+0.00%
SLNCFSilence Therapeutics plc
$1.50+0.00%
SPHDFSanthera Pharmaceuticals Holding AG
$23.25+0.00%
GNFTFGenfit S.a.
$15.95+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About OPORF

What is the current price of hVIVO Plc?

hVIVO Plc is trading at $0.11 per share.

What is the 52-week range for hVIVO Plc?

Over the past 52 weeks, hVIVO Plc has traded between $0.09 and $0.24.

How much debt does hVIVO Plc have?

As of the most recent reporting period, hVIVO Plc reported total debt of £19.89M.

How much cash does hVIVO Plc have on hand?

hVIVO Plc reported £19.23M in cash and cash equivalents in its most recent financial results.

What is hVIVO Plc’s dividend yield?

hVIVO Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services